Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPItrue: capivasertib plus fulvestrant in HR-positive/HER2-negative advanced breast cancer after prior endocrine therapy
CTR20242809Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capivasertib, fulvestrant in breast cancer, sponsored by AstraZeneca. Started Oct 2024; status: active.
02
Drugs
capivasertibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20242809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242809.